Travere Therapeutics (TVTX) On Record FILSPARI Sales And A Fair Value Gap
Travere Therapeutics (TVTX) has drawn fresh attention after reporting record revenue and net product sales tied to FILSPARI demand in multiple indications, alongside pipeline expansion, patent work and ongoing clinical trial progress.
See our latest analysis for Travere Therapeutics.
Travere Therapeutics' latest Q2 results, record FILSPARI sales and the addition of civorebrutinib have coincided with an 8.3% 1 month share price return and a 44.2% 3 month share price return. The 1 year total shareholder return of 226.4% and 3 year total shareholder return of about 3.5x suggest strong momentum rather than a short term swing.
If Travere Therapeutics has you looking more closely at kidney and rare disease treatment, it could be a good moment to broaden your watchlist with 44 healthcare AI stocks
Travere Therapeutics now trades at a sizeable discount to both analyst targets and some intrinsic value estimates after a sharp re rating. Is that discount a margin of safety, or a warning the market is still cautious?
Most Popular Narrative: 10.1% Undervalued
Travere Therapeutics closed at $61.43 compared with a widely followed fair value narrative of $68.36, which frames the recent share price strength as still leaving upside on the table.
Strong momentum in FILSPARI's uptake for IgA nephropathy, with a broadening prescriber base, increasing initiation earlier in patient treatment, positive real-world clinical feedback, and pending updates to guidelines and REMS requirements. All of these are expected to support sustained and deeper market penetration, boosting recurring revenue and improving operating leverage.
Want to see what sits underneath that confidence in Travere Therapeutics? The narrative leans heavily on faster sales growth, rising margins, and a richer earnings profile. Curious how those moving parts combine into one fair value number.
Result: Fair Value of $68.36 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Travere Therapeutics narrative still faces real tests, including competition around FILSPARI and regulatory or pricing decisions that could reshape longer term earnings power.
Find out about the key risks to this Travere Therapeutics narrative.
Next Steps
Feeling encouraged by the optimism around Travere Therapeutics, but not completely convinced yet? Take a closer look at the details for yourself and decide how much weight to put on these rewards by checking the 3 key rewards
Looking for more investment ideas beyond Travere Therapeutics?
If Travere Therapeutics has sharpened your focus on healthcare, do not stop there. Use the Simply Wall Street screener to spot other companies that might fit your style.
- Target potential mispricings by scanning for quality companies trading at appealing valuations through the 51 high quality undervalued stocks.
- Prioritise capital preservation by zeroing in on companies flagged in the 88 resilient stocks with low risk scores.
- Hunt for overlooked opportunities by filtering the market with the screener containing 18 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com